Shanghai Fosun Pharmaceutical Group Co Stock

Shanghai Fosun Pharmaceutical Group Co Equity 2024

Shanghai Fosun Pharmaceutical Group Co Equity

45.68 B CNY

Ticker

600196.SS

ISIN

CNE000000X38

In 2024, Shanghai Fosun Pharmaceutical Group Co's equity was 45.68 B CNY, a 2.47% increase from the 44.58 B CNY equity in the previous year.

Shanghai Fosun Pharmaceutical Group Co Aktienanalyse

What does Shanghai Fosun Pharmaceutical Group Co do?

Shanghai Fosun Pharmaceutical Group Co Ltd is a Chinese company specializing in the healthcare industry. It was founded in 1994 and is headquartered in Shanghai. The company has grown to become one of the largest pharmaceutical conglomerates in China and operates internationally. The company's history began in the 1990s with the establishment of Shanghai Fosun High-Tech (Group) Co. Ltd. Through the acquisition of local pharmaceutical companies, Fosun quickly secured a place among the major players in the Chinese pharmaceutical market. From the beginning, the development, production, and marketing of pharmaceutical products and medical devices were the main focus. Today, Shanghai Fosun Pharmaceutical is a holding company with various subsidiaries operating in different areas of medicine. These include the development of innovative drugs, the production of generic drugs, and the business-to-consumer sector. The company generates an annual revenue of over six billion US dollars. One of Shanghai Fosun Pharmaceutical's most well-known products is the drug Alunbrig for the treatment of lung cancer. It is a tyrosine kinase inhibitor that inhibits the growth of cancer cells. Alunbrig has shown good results in clinical studies and is now approved for the treatment of lung cancer in many countries. Another important business area for Shanghai Fosun Pharmaceutical is the production of generic drugs. These are imitations of already approved, often expensive, original drugs. Fosun manufactures such medications at a significantly lower cost than the original manufacturer, making them more accessible to a broader population. In addition to drug development and generic production, Shanghai Fosun Pharmaceutical is also active in other areas of the healthcare industry. In recent years, the company has acquired several private hospitals in China and operates them under the name Fosun International Hospitals. Special emphasis is placed on state-of-the-art medical technology and patient-oriented care. Another important area is the manufacturing of medical devices. Shanghai Fosun Pharmaceutical works closely with partners from both domestic and foreign markets to develop innovative products. An example is the artificial hip joint, which was developed in collaboration with an American partner company. Fosun produces and distributes over 70 different types of medical devices. In summary, Shanghai Fosun Pharmaceutical Group is an innovative company specializing in various areas of the healthcare industry. Through its consistent focus on growth and innovation, Fosun has steadily expanded in recent years and has become one of the key players in the Chinese pharmaceutical market. However, the global expansion and ambitious goals also leave room for risks and mistakes. Shanghai Fosun Pharmaceutical Group Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Shanghai Fosun Pharmaceutical Group Co's Equity

Shanghai Fosun Pharmaceutical Group Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Shanghai Fosun Pharmaceutical Group Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Shanghai Fosun Pharmaceutical Group Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Shanghai Fosun Pharmaceutical Group Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Shanghai Fosun Pharmaceutical Group Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Shanghai Fosun Pharmaceutical Group Co stock

What is the equity of Shanghai Fosun Pharmaceutical Group Co this year?

Shanghai Fosun Pharmaceutical Group Co has equity of 45.68 B CNY this year.

What was the equity of Shanghai Fosun Pharmaceutical Group Co compared to the previous year?

The equity of Shanghai Fosun Pharmaceutical Group Co has increased/decreased by 2.47% increased compared to the previous year.

What impact does a high equity have on investors of Shanghai Fosun Pharmaceutical Group Co?

A high equity is advantageous for investors of Shanghai Fosun Pharmaceutical Group Co as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Shanghai Fosun Pharmaceutical Group Co?

A low equity can be a risk for investors of Shanghai Fosun Pharmaceutical Group Co, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Shanghai Fosun Pharmaceutical Group Co affect the company?

An increase in equity of Shanghai Fosun Pharmaceutical Group Co can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Shanghai Fosun Pharmaceutical Group Co affect the company?

A reduction in equity of Shanghai Fosun Pharmaceutical Group Co can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Shanghai Fosun Pharmaceutical Group Co?

Some factors that can affect the equity of Shanghai Fosun Pharmaceutical Group Co include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Shanghai Fosun Pharmaceutical Group Co so important for investors?

The equity of Shanghai Fosun Pharmaceutical Group Co is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Shanghai Fosun Pharmaceutical Group Co take to change the equity?

To change equity, Shanghai Fosun Pharmaceutical Group Co can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Shanghai Fosun Pharmaceutical Group Co pay?

Over the past 12 months, Shanghai Fosun Pharmaceutical Group Co paid a dividend of 0.42 CNY . This corresponds to a dividend yield of about 1.89 %. For the coming 12 months, Shanghai Fosun Pharmaceutical Group Co is expected to pay a dividend of 0.44 CNY.

What is the dividend yield of Shanghai Fosun Pharmaceutical Group Co?

The current dividend yield of Shanghai Fosun Pharmaceutical Group Co is 1.89 %.

When does Shanghai Fosun Pharmaceutical Group Co pay dividends?

Shanghai Fosun Pharmaceutical Group Co pays a quarterly dividend. This is distributed in the months of August, July, September, September.

How secure is the dividend of Shanghai Fosun Pharmaceutical Group Co?

Shanghai Fosun Pharmaceutical Group Co paid dividends every year for the past 23 years.

What is the dividend of Shanghai Fosun Pharmaceutical Group Co?

For the upcoming 12 months, dividends amounting to 0.44 CNY are expected. This corresponds to a dividend yield of 2 %.

In which sector is Shanghai Fosun Pharmaceutical Group Co located?

Shanghai Fosun Pharmaceutical Group Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Shanghai Fosun Pharmaceutical Group Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Shanghai Fosun Pharmaceutical Group Co from 8/6/2024 amounting to 0.27 CNY, you needed to have the stock in your portfolio before the ex-date on 8/6/2024.

When did Shanghai Fosun Pharmaceutical Group Co pay the last dividend?

The last dividend was paid out on 8/6/2024.

What was the dividend of Shanghai Fosun Pharmaceutical Group Co in the year 2023?

In the year 2023, Shanghai Fosun Pharmaceutical Group Co distributed 0.56 CNY as dividends.

In which currency does Shanghai Fosun Pharmaceutical Group Co pay out the dividend?

The dividends of Shanghai Fosun Pharmaceutical Group Co are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Shanghai Fosun Pharmaceutical Group Co

Our stock analysis for Shanghai Fosun Pharmaceutical Group Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Shanghai Fosun Pharmaceutical Group Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.